依达拉奉联合丁苯酞治疗急性缺血性脑卒中疗效及安全性评价

Evaluation of efficacy and safety of edaravone combined with butylphthalide in the treatment of acute ischemic stroke

目的:探讨依达拉奉联合丁苯酞治疗急性缺血性脑卒中的临床疗效及安全性。方法:收集2016年1月至2018年6月治疗的急性缺血性脑卒中患者100例,按照治疗方案不同分为观察组和对照组各50例。对照组给予丁苯酞治疗,对照组静脉滴注丁苯酞氯化钠注射液2次/d,25mg/次,连续2周。观察组静脉滴注丁苯酞氯化钠注射液2次/d,25mg/次;依达拉奉注射液30mg/次加至100ml0.9%氯化钠注射液中静脉滴注,2次/d,治疗2周。比较两组临床疗效、治疗期间不良反应发生率及治疗前后美国国立卫生院卒中量表(NIHSS)评分和Barthel指数(BI)变化情况。结果:观察组疗效94.00%(47/50),优于对照组的80.00%(40/50,P<0.05)。治疗后观察组NIHSS评分和BI评分分别为(12.12±2.37)分和(88.85±6.95)分,优于对照组的(16.17±2.68)分和(75.27±6.31)分,组间差异有统计学意义(P<0.05)。观察组出现不良反应2例,对照组7例,组间差异无统计学意义(P>0.05)。结论:依达拉奉联合丁苯酞治疗急性缺血性脑卒中疗效显著,安全性良好,值得临床推荐。

Objective: To investigate the clinical efficacy and safety of edaravone combined with butylphthalide in the treatment of acute ischemic stroke. Methods: One hundred patients with acute ischemic stroke treated from January 2016 to June 2018 were collected and divided into an observation group and a control group with 50 cases in each group according to different treatment schemes. The control group was treated with butylphthalide, and the control group received intravenous injection of sodium butylphthalide chloride twice a day, 25 mg/time for 2 weeks. The observation group received intravenous drip of sodium butylphthalide chloride injection twice a day, 25 mg a time;intravenous infusion of edaravone injection 30 mg/time to 100 ml 0.9% sodium chloride injection, twice a day, for 2 weeks. The clinical efficacy, the incidence of adverse reactions during treatment, and the changes of the National Institutes of Health Stroke Scale(NIHSS) score and Barthel index(BI) before and after treatment were compared between the two groups. Results: The curative effect of the observation group was 94.00%(47/50), which was better than that of the control group 80.00%(40/50, P<0.05). The NIHSS score and BI score of the observation group were (12.12±2.37) and (88.85±6.95), respectively, which were better than those of the control group(16.17±2.68) and (75.27±6.31), and the difference between the groups was statistically significant(P<0.05). There were 2 cases of adverse reactions in the observation group and 7 cases in the control group, and there was no significant difference between the two groups(P>0.05). Conclusion: Edaravone combined with butylphthalide is effective and safe in the treatment of acute ischemic stroke, which is worthy of clinical recommendation.